Cargando…

Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema

PURPOSE: To evaluate outcome of intravitreal dexamethasone implant (IDI) treatment on serous retinal detachment (SRD) in patients with ranibizumab-resistant diabetic macular edema (DME). MATERIALS AND METHODS: Forty-eight eyes of 48 patients with DME resistant to ranibizumab were enrolled in this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayat, Alper Halil, Elçioğlu, Mustafa Nuri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658505/
https://www.ncbi.nlm.nih.gov/pubmed/33225213
http://dx.doi.org/10.1177/2515841420971936
_version_ 1783608685549846528
author Bayat, Alper Halil
Elçioğlu, Mustafa Nuri
author_facet Bayat, Alper Halil
Elçioğlu, Mustafa Nuri
author_sort Bayat, Alper Halil
collection PubMed
description PURPOSE: To evaluate outcome of intravitreal dexamethasone implant (IDI) treatment on serous retinal detachment (SRD) in patients with ranibizumab-resistant diabetic macular edema (DME). MATERIALS AND METHODS: Forty-eight eyes of 48 patients with DME resistant to ranibizumab were enrolled in this retrospective and comparative study. Patients were divided into two groups according to presence of serous retinal detachment: (1) SRD or (2) non-SRD groups. All patients had at least three monthly ranibizumab injections, after which they were treated with IDI. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), use of antiglaucomatous drugs, and presence of cataract progression were noted at 1, 3, and 6 months post-IDI treatment. RESULTS: There was not any statistically significant difference in terms of baseline characteristics of the patients. The mean CRT was declined in both groups at 1, 3, and 6 months (p < 0.001). After IDI treatment, the mean BCVA was improved in both groups at 1, 3, and 6 months (p < 0.001). When groups were compared, the change in CRT was higher in the SRD group (p = 0.018), while there was no statistically significant difference between groups in terms of BCVA changes (p = 0.448). CONCLUSION: The presence of SRD resulted in higher anatomical gain. SRD had no effects on visual changes after dexamethasone treatment in patients with ranibizumab-resistant DME.
format Online
Article
Text
id pubmed-7658505
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76585052020-11-20 Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema Bayat, Alper Halil Elçioğlu, Mustafa Nuri Ther Adv Ophthalmol Original Research PURPOSE: To evaluate outcome of intravitreal dexamethasone implant (IDI) treatment on serous retinal detachment (SRD) in patients with ranibizumab-resistant diabetic macular edema (DME). MATERIALS AND METHODS: Forty-eight eyes of 48 patients with DME resistant to ranibizumab were enrolled in this retrospective and comparative study. Patients were divided into two groups according to presence of serous retinal detachment: (1) SRD or (2) non-SRD groups. All patients had at least three monthly ranibizumab injections, after which they were treated with IDI. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), use of antiglaucomatous drugs, and presence of cataract progression were noted at 1, 3, and 6 months post-IDI treatment. RESULTS: There was not any statistically significant difference in terms of baseline characteristics of the patients. The mean CRT was declined in both groups at 1, 3, and 6 months (p < 0.001). After IDI treatment, the mean BCVA was improved in both groups at 1, 3, and 6 months (p < 0.001). When groups were compared, the change in CRT was higher in the SRD group (p = 0.018), while there was no statistically significant difference between groups in terms of BCVA changes (p = 0.448). CONCLUSION: The presence of SRD resulted in higher anatomical gain. SRD had no effects on visual changes after dexamethasone treatment in patients with ranibizumab-resistant DME. SAGE Publications 2020-11-10 /pmc/articles/PMC7658505/ /pubmed/33225213 http://dx.doi.org/10.1177/2515841420971936 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Bayat, Alper Halil
Elçioğlu, Mustafa Nuri
Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
title Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
title_full Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
title_fullStr Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
title_full_unstemmed Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
title_short Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
title_sort effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658505/
https://www.ncbi.nlm.nih.gov/pubmed/33225213
http://dx.doi.org/10.1177/2515841420971936
work_keys_str_mv AT bayatalperhalil effectsofdexamethasonetreatmentonserousretinaldetachmentinranibizumabresistantdiabeticmacularedema
AT elcioglumustafanuri effectsofdexamethasonetreatmentonserousretinaldetachmentinranibizumabresistantdiabeticmacularedema